Hot Investor Mandate: VC Firm Invests Up to $50M, Open to All Revenue-Generating Technologies Within Life Sciences & Healthcare with Meaningful Marketplace Validation

A firm based in the USA and investing out of their third fund currently makes equity investments in commercial stage (post regulatory approval) healthcare companies with meaningful revenue and traction. The firm typically invests between $15-$50m per company.

The firm invests exclusively in healthcare and is open to all sub-sectors within the industry. That said, the firm does not invest in pre-revenue companies or those with regulatory risk; investments are made in revenue-generating companies with products that have already received regulatory approval or which do not require regulatory approval. The firm looks for companies with meaningful marketplace validation and growing revenues, where the firm’s investment could help to accelerate the adoption.

The firm prefers to invest in management teams with experience in leading and growing businesses of scale and relevant industry experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Asia-Based Pharmaceutical Seeks Global R&D Partnerships and Investment in Drugs, Devices, and More With Strong Interest in Anti-Infectives and Oncology

A listed pharmaceutical company with $5 Billion of assets under management has become a high-tech pharmaceutical health industry cluster that covers manufacturing, R&D, and sales in the pharmaceutical area after 2 decades of arduous efforts. The firm is open to global R&D partnerships and investment opportunities.

The firm has a focused interest in finished drugs, pharmaceutic adjuvants, active pharmaceutical ingredients, medical devices, medical and health management services. In addition, the firm pays special attention to novel therapeutic innovations in sepsis, anti-infection, and oncology area.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Eli Lilly Comes to RESI

By Antoinette Lowre, Manager of Business Development, LSN

Eli Lilly joins RESI Boston, September 21-23, providing insight from the large pharma to the RESI community of early-stage players. Eli Lilly is committed to creating high-quality medicines through every aspect of business and the people they serve, stating that “Lilly unites caring with discovery to create medicines that make life better for people around the world.” This is central to Life Science Nation (LSN)’s mission of connecting early-stage life science with capital and channel partners to see healthcare advance. We are thrilled to bring Eli Lilly to RESI to add value to the community and provide new opportunities for investors and founders to gain more exposure to early-stage life science players.

In addition to a Title Sponsorship, Eli Lilly will send a team to source assets within the following sectors and indications:

  1. Genetic Medicine – RNA, Gene-editing, and Gene therapy, including associated delivery technology (e.g. next-gen AAV capsids and non-viral approaches)
  2. Neuroscience, including technology and tools to achieve CNS delivery of therapeutics.
  3. Obesity/Diabetes, including approaches to broaden therapeutic administration routes.

If your product and technology align with these sectors, reach out to us to connect with Eli Lilly at RESI Boston.  Partnering opens soon, so sign up today!

To explore the full breath of Lilly’s interests please visit https://www.lilly.com/partners.

RESI-Boston-2022-Banner-with-lilly-logo-1100px

LSN Partners with Shinhan Square Bridge (S2 Bridge), a Global Startup Acceleration Platform

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

Life Sciencen Nation (LSN)’s latest partnership features Shinhan Square Bridge (S2 Bridge), a Startup Acceleration Platform based in Songdo, Incheon Metropolitan City in South Korea. Throughout the past several years, we have collaborated with many Korean organizations to support the global expansion of promising early-stage life science companies. S2 Bridge will bring seven startups to RESI Boston, September 21-23, to be showcased during a 2-hour dedicated pitch session. Below are the participating companies:

LSN’s mission to facilitate connections between life science startups and investors and strategic partners is central to these partnerships, bringing S2 Bridge and their participating startups to increase their visibility to our global ecosystem. Ji Sun (Julia) Lee, CEO of S2 Bridge said, “South Korea’s biotech industry has made significant progress throughout the ongoing pandemic and is only continuing to grow. As global partnerships and collaborations are key to success particularly in the life science industry, we hope that our partnership with LSN and RESI serves as an opportunity to properly showcase Korean startups and their innovativeness to the global market.”

Learn more about S2 Bridge and their partnering organizations:

Shinhan Square Bridge (S2 Bridge) Incheon

With the motto of “One Place, One Platform”, 『Shinhan Square Bridge (S2 Bridge) Incheon』 is a platform that supports the growth of startups in cooperation with government agencies and the private sector. S2 Bridge was established as the first public-private Startup Acceleration Platform in South Korea, with the dream of becoming a global startup innovation growth hub.

S2 Bridge is located in Songdo, a city in South Korea recognized as a global business center and biocluster. Key partnering organizations include Shinhan Financial Group, a leading global financial group that supports an innovative investment ecosystem, and Celltrion, a global biotech company that supports open innovation opportunities to accelerate promising biotech startups, and Incheon Metropolitan City that actively helps to foster the local biotech infrastructure. From the seed to global expansion stage, S2 Bridge focuses on accelerating life science startups based on their innovative technologies. The firm focuses on startups in all fields of life sciences, including novel therapeutics, microbiome, medical devices, and digital health to enter the global market and attract investment.

S2 Bridge operates a one-stop investment platform with Incheon Metropolitan City and Incheon Free Economic Zone Authority (IFEZ) and supports open innovation with Shinhan Financial Group and Celltrion. Moreover, the firm supports networking and content for the expansion of the startup ecosystem by holding global conferences and providing media promotion, among other activities. The firm also provides a working space optimized for the startups’ business growth to all startup members.

Since launching in November 2020, S2 Bridge has discovered and accelerated 155 promising startups with innovative technologies, and achieved investment attraction of 135.4 billion KRW (~$102M USD), a corporate value growth rate of 90.2%, and 252 cases of open innovation and resource linkage with public-private partnership.

Shinhan Financial Group / Shinhan Financial Group Hope Foundation

Shinhan Financial Group was founded in 2001 as the first private financial holding company in Korea and covers the entire financial industry with 15 group companies and continues to make the way for the global dream to become reality through 200 channels in 20 countries.

With the group’s vision of “Easier, More Comfortable, Newer Finance”, the group provides customers with various financial services to improve society as a whole. The group is taking the lead in establishing common value for mankind with the Group’s Environment, Social, Governance (ESG) Slogan of “Do the Right Thing for a Wonderful World” and is continuing the mission of “Benefitting the World through Finance”, taking pride in the group’s 40-year history of innovation.

Shinhan Financial Group Hope Foundation is a leading first-class, non-profit public interest corporation that promotes the sustainable development of companies, foundations, and CSR projects. The goal is to contribute to the development of the local community through supporting education, art and culture, employment support, and helping people with financial vulnerability.

Incheon Metropolitan City / Incheon Free Economic Zone Authority

Incheon Metropolitan City and Incheon Free Economic  Zone Authority (IFEZ) is located in the center of the Northeast Asian Economic Zone (Songdo) and actively works to create an innovative Startup Ecosystem. Based on world-class business infrastructure, the city of Incheon is creating synergy through high-tech industries and collaborations with renowned industries, universities, and research institutes to create a leading global market. Through these efforts, Incheon seeks to leap forward as the world’s largest bio-healthcare complex and lead the 4th industrial revolution. Leading domestic and international bio companies have moved in and are actively engaged in business activities. In the future, Incheon will flourish with synergistic accomplishments through the establishment of a bio-convergence industrial technology complex.

Presenting a new role model for future smart cities and establishing an urban innovation platform, Incheon Metropolitan City and IFEZ seek to become an eco-friendly city where people and nature co-exist.

Celltrion

Celltrion is Korea’s leading global biotechnology company that pioneered antibody biosimilars for the first time in the pharmaceutical industry. Celltrion has made remarkable achievements by pioneering a path that others have not taken, and rapidly grown into a global biotechnology company based on differentiated business strategies such as the development of chemical drugs, new drugs, and the U-Health Care Platform. Through these strategies, Celltrion is growing into a global comprehensive biotechnology company that promotes the value of advancing human health and welfare.

RESI-Boston-2022-Banner-with-lilly-logo-1100px

Partnering Opens Soon

By Karen Deyo, Director of Investor Research, Israel BD, LSN

RESI Boston is rapidly approaching, and the partnering platform launch is just around the corner. Opening on August 29, attendees will be able to book meetings at our first hybrid event, either meeting in person on September 21-22, or virtually on September 23. As a partnering-focused event, much effort is made to ensure startups can identify and request meetings with investors and strategic partners who are a fit for them. Additionally, attendees can take advantage of the first in-person RESI since January of 2020 to make unexpected connections through ad hoc meetings and networking opportunities.

Sign up for our free partnering tutorials below and register for RESI before partnering opens to have as much time as possible to maximize your partnering experience!

RESI Boston Partnering Tutorial

August 31, Wednesday Sign Up

September 6, Tuesday Sign Up

RESI-Boston-2022-Banner-with-lilly-logo-1100px

Hot Investor Mandate: PE Firm With Virtual Pharma Model Invests in Promising Early Stage Therapeutic Assets Across the Globe, Providing Up to $25M in Funding

An innovative private equity firm and investment fund utilizes the virtual pharma (‘asset-centric’) model and invests in early stage pharmaceutical assets (i.e., small molecules and biologics, including cell and gene therapies), and provides up to $25 million, or more, to fund each project, typically through Phase 2 clinical proof-of-concept, before exiting through sales of successful assets to major pharmaceutical companies. The firm prefers to invest in individual assets through innovative deal structures, and is less likely to make traditional equity investments in companies. The company founders continue to lead development of their asset. Ideal investment candidates have yet to receive significant VC funding, and the firm prefers to invest without typical syndicates. The firm integrates each company’s founders and their asset into a dedicated special purpose vehicle and collaborates closely with them — providing broad and deep drug development expertise and resources to maximize product value. The firm invests in projects around the globe and aims to maintain an ongoing investment portfolio of 15-25 high quality assets.

The firm seeks biopharmaceutical drug assets — small molecules, biologics, and cell or gene therapies. The firm is willing to invest in drug candidates that are up to 12-18 months pre-IND, as well as those that are in, or have completed, Phase I clinical trial(s). Ideal candidates are ‘IND-ready’, patent-protected in all major pharma markets, and represent both potential solutions to major unmet medical needs and significant market potential. The firm is open to all therapeutic areas and indications for which proof-of-concept can be evaluated in early clinical trials, including single asset companies managed by small experienced teams.

The firm is looking to partner with founders and associates with a deep understanding of the science and pharmacology underlying their product, and who are willing to operate in a highly collaborative, virtual and global environment. Such willingness to collaborate is essential because the firm acts as a hands-on investor and partner — contributing its extensive drug development expertise, operational resources and industry connections to each company’s asset to ensure all assets are developed in the most efficient and effective manner, with a particular focus on early development de-risking.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Firm With US and Israel Offices Seeks Pre-Seed and Seed Stage Companies, Strong Interest in Therapeutics and Diagnostics

A venture firm with offices in US and Israel invests in multiple sectors, including the life sciences. The firm invests in pre-seed and seed stage companies; within healthcare, therapeutics, diagnostics and R&D tools companies developing platform technologies. The firm invests early, often acting as the first institutional capital, investing just after the initial stages of product development. The firm generally leads rounds, investing between $.5-5M in rounds no larger than ~$7M. While the firm has to this point invested in US and Israeli companies, it will also consider European and Canadian companies as well.

Within healthcare, the firm is interested in platform technologies in therapeutics and diagnostics/R&D tools. The firm is agnostic to indication and modality, and is looking for companies that have multiple avenues of development to reach the market. Previous investments include companies building CRISPR technologies, post-treatment monitoring, -omics-based drug development, CAR-T and high-throughput screening. The firm does not invest in digital health or medical devices.

The firm acts as a lead investor. Even though they invest early, the firm prefers that the company have at least two full time co-founders before investing. The firm does take a board seat after investing, and is an active investor.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.